NCT02540954 - Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) | Biotech Hunter

Enrollment

336

Participants

Timeline

Start Date

September 29, 2015

Primary Completion Date

December 24, 2019

Study Completion Date

June 4, 2020

Conditions

Macular Degeneration

Interventions

DRUG

Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

A dose of 2 mg aflibercept injected intravitreally

Trial Locations (71)

1085

Budapest

1090

Vienna

1140

Vienna

1204

Geneva

4032

Debrecen

7621

Pécs

10122

Turin

10713

Berlin

12203

Berlin

12808

Prague

16132

Genoa

20122

Milan

20132

Milan

20157

Milan

20251

Hamburg

25015

Brescia

33000

Bordeaux

35037

Marburg

37075

Göttingen

37134

Verona

40225

Düsseldorf

43126

Parma

46014

Valencia

56124

Pisa

60596

Frankfurt am Main

64297

Darmstadt

69317

Lyon

75010

Paris

75557

Paris

95123

Catania

97080

Würzburg

M4N 3M5

Toronto

J1J 2B8

Clinique medicale de l'oeil de l'Estrie, Sherbrooke

500 05

Hradec Králové

304 60

Pilsen

100 34

Prague

150 00

Prague

BP 1542-21

Dijon

06006

Nice

04103

Leipzig

00133

Rome

00198

Rome

LT-50009

Kaunas

LT-08661

Vilnius

80-809

Gdansk

10-424

Olsztyn

3000-548

Coimbra

2410-197

Leiria

1649-035

Lisbon

4200-319

Porto

826 06

Bratislava

851 07

Bratislava

949 01

Nitra

08907

L'Hospitalet de Llobregat

08036

Barcelona

Unknown

Bern

SO16 6YD

Southampton

L7 8XP

Liverpool

NR31 6LA

Great Yarmouth

TS4 3BW

Middlesbrough

CF72 8XR

Pont-y-clun

GU2 7XX

Guildford

NE1 4LP

Newcastle upon Tyne

SR2 9HP

Sunderland

CV22 5PX

Rugby

WF1 4DG

Wakefield

HU3 2JZ

Hull

CO3 3NB

Colchester

NW1 5QH

London

SE5 9RS

London

M13 9WL

Manchester